Arrowhead Pharmaceuticals, Inc.
ARWR
$79.04
$1.301.67%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -109.01% | 131.62% | 99.73% | 72.45% | 69.42% |
| Total Depreciation and Amortization | 20.07% | 28.19% | 28.68% | 29.48% | 32.68% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 48.74% | 83.92% | 88.79% | 27.62% | 24.84% |
| Change in Net Operating Assets | -0.91% | -354.48% | -172.68% | -63.01% | -34.06% |
| Cash from Operations | -159.37% | 169.07% | 138.79% | 106.21% | 123.80% |
| Capital Expenditure | 71.74% | 78.47% | 83.98% | 78.21% | 75.83% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -35.79% | 35.10% | 61.73% | -2,767.47% | -1,806.70% |
| Cash from Investing | -25.88% | 43.64% | 69.22% | -154.94% | -204.79% |
| Total Debt Issued | 81.19% | -97.38% | -97.38% | -- | -- |
| Total Debt Repaid | 11.29% | -- | -- | -- | -- |
| Issuance of Common Stock | -22.92% | -31.33% | -43.16% | -43.30% | -43.36% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -134.14% | -100.00% | -57.33% | -66.27% | -- |
| Cash from Financing | 34.29% | -95.66% | -91.50% | -4.73% | 27.60% |
| Foreign Exchange rate Adjustments | -67.83% | -105.58% | -109.55% | 28,178.57% | 2,205.70% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -95.16% | 3,515.49% | 1,609.42% | 268.06% | 899.52% |